TG Therapeutics (NASDAQ:TGTX) Downgraded to Strong Sell Rating by Zacks Research
Zacks Research lowered shares of TG Therapeutics (NASDAQ:TGTX – Free Report) from a hold rating to a strong sell rating in a research note published on Monday,Zacks reports. Other equities analysts also recently issued reports about the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $83.00 target price on shares of TG […]
9 Sep 11:54 · The Markets Daily